{"id":556983,"date":"2021-08-10T18:14:01","date_gmt":"2021-08-10T18:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556983"},"modified":"2021-08-10T18:14:01","modified_gmt":"2021-08-10T18:14:01","slug":"surgical-site-infections-ssi-market-insight-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/surgical-site-infections-ssi-market-insight-epidemiology-and-market-forecast-2030_556983.html","title":{"rendered":"Surgical Site Infections (SSI) Market Insight, Epidemiology and Market Forecast – 2030"},"content":{"rendered":"
\n
\"Surgical<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Surgical Site Infection Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the Surgical Site Infection (SSI), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n<\/div>\n

Surgical Site Infections Ssi Market<\/strong><\/p>\n

The Surgical Site Infection (SSI) market report<\/strong><\/a> provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted SSI symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Surgical Site Infection (SSI) symptoms treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n

Surgical Site Infection (SSI) Epidemiology<\/strong><\/p>\n

The epidemiology division’s Surgical Site Infection symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.<\/p>\n

 <\/p>\n

Key Findings<\/p>\n

The disease epidemiology covered in the report provides historical as well as forecasted Surgical Site Infection (SSI) epidemiology segmented as the Total Surgical Procedures, Number of Surgical Procedures by Type, Total Incident cases of Surgical Site Infections (SSI) and Incidence of Surgical Site Infections (SSI) by Type. The report includes the Incident scenario of SSI symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.<\/p>\n

Country-wise Surgical Site Infection (SSI) Epidemiology<\/strong><\/p>\n

The epidemiology segment also provides the Surgical Site Infection (SSI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/p>\n

 <\/p>\n

The total 7MM incident cases of Surgical Site Infection (SSI) were 1,275,912 in 2020.<\/p>\n

Surgical Site Infection (SSI) Drug Chapters<\/strong><\/p>\n

The drug chapter segment of the Surgical Site Infection (SSI) report encloses the detailed analysis of SSI marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Surgical Site Infection (SSI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.<\/p>\n

 <\/p>\n

The surgical Site Infection (SSI) Treatment drug market is based on antibiotics such as Vancomycin and Linezolid (Cardiothoracic\/related leg SSI), and Tigecycline IV (Abdominal SSI). Due to their easy availability and reach, these drugs have a higher penetration rate in the market, thereby adding up to the total revenue generated.<\/p>\n

Products detail in the report…<\/p>\n

 <\/p>\n

Surgical Site Infection (SSI) Emerging Drugs<\/strong><\/a><\/p>\n

 <\/p>\n

XF-73 (Exeporfinium Chloride) is a synthetic dicationic porphyrin derivative with antibacterial activity for the patients at risk of postoperative staphylococcal infection. XF-73 by Destiny Pharma belongs to a new class of drugs known as XF drugs and has confirmed bactericidal activity with a novel mechanism of action that differs from that of any existing families of antimicrobial agents. The US FDA has granted the drug Fast Track Designation to prevent post-surgical staphylococcal infections such as Methicillin-resistant Staphylococcus aureus (MRSA).<\/p>\n

Products detail in the report…<\/p>\n

Surgical Site Infection (SSI) Market Outlook<\/strong><\/p>\n

The Surgical Site Infection (SSI) market outlook<\/strong><\/a> of the report helps build the detailed comprehension of the historic, current and forecasted Surgical Site Infection (SSI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.<\/p>\n

 <\/p>\n

This segment gives a thorough detail of Surgical Site Infection (SSI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n

 <\/p>\n

According to DelveInsight, Surgical Site Infection (SSI) market in 7MM is expected to change in the study period 2018–2030.<\/p>\n

 <\/p>\n

Key Findings<\/p>\n

This section includes a glimpse of the Surgical Site Infection (SSI) market in 7MM. The prophylactic market size of SSI in the seven major markets was USD 418.79 million in 2020, which is estimated to increase at a CAGR of 22.84% for the study period (2018–2030). Similarly, the treatment market size of SSI was USD 648.86 million in 2020, and the market is estimated to decline at a CAGR of −1.88%.<\/p>\n

 <\/p>\n

The United States Market Outlook<\/p>\n

This section provides a total of Surgical Site Infection (SSI) market size and market size by therapies in the United States.<\/p>\n

 <\/p>\n

The United States accounts for the largest SSI market size than the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.<\/p>\n

 <\/p>\n

In Nov 2020, PolyPid Ltd. announced that D-PLEX100 received Breakthrough Therapy Designation from the US Food and Drug Administration to prevent surgical site infections (SSIs) in patients undergoing elective colorectal surgery. D-PLEX100 has the potential to transform the prevention of SSIs radically. D-PLEX100 is being developed to manage bone and soft tissue SSIs in the cardiac and abdominal surgery segment.<\/p>\n

 <\/p>\n

The dynamics of both prophylactic and surgical site infection treatment market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2021–2030. There are presently three emerging therapies focused on treating or preventing surgical site infection in either cardio or abdominal surgeries.<\/p>\n

 <\/p>\n

EU-5 Countries: Market Outlook<\/p>\n

The total Surgical Site Infection (SSI) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.<\/p>\n

 <\/p>\n

Prophylactic Therapy segment is XF-73 under development by Destiny Pharma with its antimicrobial “XF” drug platform. XF-73 was awarded QIDP status in October 2015.<\/p>\n

 <\/p>\n

Japan Market Outlook<\/p>\n

The total Surgical Site Infection (SSI) market size and market size by therapies in Japan are also mentioned.<\/p>\n

Request for sample pages @ Surgical Site Infection Market Size<\/a><\/strong><\/p>\n

Table of contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Report Introduction<\/p>\n

3. Surgical Site Infection Prophylactic Market Overview at a Glance<\/p>\n

3.1. Prophylactic Market Share (%) Distribution of Surgical Site Infection in 2018<\/p>\n

3.2. Prophylactic Market Share (%) Distribution of Surgical Site Infection in 2030<\/p>\n

4. Surgical Site Infection Treatment Market Overview at a Glance<\/p>\n

4.1. Treatment Market Share (%) Distribution of Surgical Site Infection in 2018<\/p>\n

4.2. Treatment Market Share (%) Distribution of Surgical Site Infection in 2030<\/p>\n

5. Executive Summary of Surgical Site Infection<\/p>\n

6. Disease Background and Overview<\/p>\n

6.1. Introduction<\/p>\n

6.2. Types<\/p>\n

6.3. Signs and Symptoms<\/p>\n

6.4. Causes<\/p>\n

6.5. Risk Factors<\/p>\n

6.5.1. Assessing Patient Risks during the Preoperative Phase<\/p>\n

6.5.2. Modifiable and Non-Modifiable Host Risk Factors<\/p>\n

6.5.3. Extrinsic or External Risk Factors<\/p>\n

6.6 Pathogenesis<\/p>\n

6.7. Diagnosis<\/p>\n

6.7.1. Diagnosis Based on Types<\/p>\n

6.7.2. Diagnosis Based on Microbes<\/p>\n

7. Epidemiology and Patient Population<\/p>\n

7.1. Key Findings<\/p>\n

7.2. 7MM Total Patient Population of Surgical Site Infection<\/p>\n

7.3. The United States<\/p>\n

7.3.1. Assumptions and Rationale<\/p>\n

7.3.2. Total Surgical Procedures in the United States<\/p>\n

7.3.3. Number of surgical procedures by types in the United States<\/p>\n

7.3.4. Total Incident cases of Surgical Site Infections in the United States<\/p>\n

7.3.5. Incidence of Surgical Site Infections by types in the United States<\/p>\n

7.4. EU5<\/p>\n

7.4.1. Assumtions and Rationale<\/p>\n

7.4.2. Germany<\/p>\n

7.4.2.1. Total Surgical Procedures in Germany<\/p>\n

7.4.2.2. Number of surgical procedures by types in Germany<\/p>\n

7.4.2.3. Total Incident cases of Surgical Site Infections in Germany<\/p>\n

7.4.2.4. Incidence of Surgical Site Infections by types in Germany<\/p>\n

7.4.3. France<\/p>\n

7.4.3.1. Total Surgical Procedures of Surgical Site Infection in France<\/p>\n

7.4.3.2. Number of surgical procedures by types in France<\/p>\n

7.4.3.3. Total Incident cases of Surgical Site Infections in France<\/p>\n

7.4.3.4. Incidence of Surgical Site Infections by types in France<\/p>\n

7.4.4. Italy<\/p>\n

7.4.4.1. Total Surgical Procedures in Italy<\/p>\n

7.4.4.2. Number of surgical procedures by types in Italy<\/p>\n

7.4.4.3. Total Incident cases of Surgical Site Infections in Italy<\/p>\n

7.4.4.4. Incidence of Surgical Site Infections by types in Italy<\/p>\n

7.4.5. Spain<\/p>\n

7.4.5.1. Total Surgical Procedures in Spain<\/p>\n

7.4.5.2. Number of surgical procedures by types in Spain<\/p>\n

7.4.5.3. Total Incident cases of Surgical Site Infections in Spain<\/p>\n

7.4.5.4. Incidence of Surgical Site Infections by types in Spain<\/p>\n

7.4.6. United Kingdom<\/p>\n

7.4.6.1. Total Surgical Procedures in the United Kingdom<\/p>\n

7.4.6.2. Number of surgical procedures by types in the United Kingdom<\/p>\n

7.4.6.3. Total Incident cases of Surgical Site Infections in the United Kingdom<\/p>\n

7.4.6.4. Incidence of Surgical Site Infections by types in the United Kingdom<\/p>\n

7.5. Japan<\/p>\n

7.5.1. Assumptions and Rationale<\/p>\n

7.5.2. Total Surgical Procedures in Japan<\/p>\n

7.5.3. Number of surgical procedures by types in Japan<\/p>\n

7.5.4. Total Incident cases of Surgical Site Infections in Japan<\/p>\n

7.5.5. Incidence of Surgical Site Infections by types in Japan<\/p>\n

8. Treatment and Management<\/p>\n

8.1. Treatment Algorithm of Surgical Site Infections (SSIs)<\/p>\n

9. Prevention<\/p>\n

9.1. Preoperative Measures<\/p>\n

9.2. Intraoperative Measures<\/p>\n

9.3. Postoperative Measures<\/p>\n

9.4. Antibiotic Prophylaxis (AP)<\/p>\n

9.5. Prevention Guideline for Surgical Site Infections (SSIs)<\/p>\n

9.5.1. Centers for Disease (CDC): Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017<\/p>\n

9.5.2. World Health Organization (WHO): Global Guidelines for the Prevention of Surgical Site Infection<\/p>\n

9.3.3. National Institute for Health and Care Excellence (NICE): Surgical Site Infections: Prevention and Treatment Guidelines<\/p>\n

10. Organizations contributing towards Surgical Site Infection<\/p>\n

11. Patient Journey<\/p>\n

12. Case Report<\/p>\n

13. Emerging Therapies<\/p>\n

13.1. XF-73: Destiny Pharma<\/p>\n

13.1.1. Drug Description<\/p>\n

13.1.2. Regulatory Milestones<\/p>\n

13.1.3. Clinical Development<\/p>\n

13.1.4. Clinical Trials Information<\/p>\n

13.1.5. Safety and Efficacy<\/p>\n

13.1.6. Product Profile<\/p>\n

13.2 D.-PLEX100: PolyPid<\/p>\n

13.2.1. Drug Description<\/p>\n

13.2.2. Regulatory Milestones<\/p>\n

13.2.3. Clinical Development<\/p>\n

13.2.4. Clinical Trials Information<\/p>\n

13.2.5. Safety and Efficacy<\/p>\n

13.2.6. Product Profile<\/p>\n

13.3 Delafloxacin: Menarini Group Pharma<\/p>\n

13.3.1. Drug Description<\/p>\n

13.3.2. Regulatory Milestones<\/p>\n

13.3.3. Clinical Development<\/p>\n

13.3.4. Clinical Trials Information<\/p>\n

13.3.5. Product Profile<\/p>\n

13.4. BTX 1801: Botanix Pharma<\/p>\n

13.4.1. Drug Description<\/p>\n

13.4.2. Regulatory Milestones<\/p>\n

13.4.3. Safety and Efficacy<\/p>\n

13.4.4. Product Profile<\/p>\n

13.5. DFA-02: Dr. Reddy’s Laboratories Ltd.<\/p>\n

13.5.1. Drug Description<\/p>\n

13.5.2. Regulatory Milestones<\/p>\n

13.5.3. Clinical Development<\/p>\n

13.5.4. Clinical Trials Information<\/p>\n

13.5.5. Safety and Efficacy<\/p>\n

13.5.6. Product Profile<\/p>\n

13.6. Zuragard: Zurex Pharma<\/p>\n

13.6.1. Drug Description<\/p>\n

13.6.2. Clinical Development<\/p>\n

13.6.3. Clinical Trials Information<\/p>\n

13.6.4. Safety and Efficacy<\/p>\n

13.6.5. Product Profile<\/p>\n

14. Surgical Site Infection: Seven Major Market Analysis<\/p>\n

14.1. Key Findings<\/p>\n

14.2. Treatment Market Size of Surgical Site Infection in 7MM<\/p>\n

14.3. Prophylactic Market Size of Surgical Site Infection in 7MM<\/p>\n

14.4. Market Outlook<\/p>\n

14.5. United States Market Size<\/p>\n

14.5.1. Prophylaxis Market Size by Therapy<\/p>\n

14.5.2. Surgical Site Infections – Treatment Market Size by Therapy<\/p>\n

14.6. EU-5 Market Size<\/p>\n

14.6.1. Germany<\/p>\n

14.6.1.1. Prophylaxis Market Size by Therapy<\/p>\n

14.6.1.2. Surgical Site Infections – Treatment Market Size by Therapy<\/p>\n

14.6.2. France<\/p>\n

14.6.2.1. Prophylaxis Market Size by Therapy<\/p>\n

14.6.2.2. Surgical Site Infections – Treatment Market Size by Therapy<\/p>\n

14.6.3. Italy<\/p>\n

14.6.3.1. Prophylaxis Market Size by Therapy<\/p>\n

14.6.3.2. Surgical Site Infections – Treatment Market Size by Therapy<\/p>\n

14.6.4 Spain<\/p>\n

14.6.4.1. Prophylaxis Market Size by Therapy<\/p>\n

14.6.4.2. Surgical Site Infections – Treatment Market Size by Therapy<\/p>\n

14.6.5. United Kingdom<\/p>\n

14.6.5.1. Prophylaxis Market Size by Therapy<\/p>\n

14.6.5.2. Surgical Site Infections – Treatment Market Size by Therapy<\/p>\n

14.7. Japan<\/p>\n

14.7.1. Prophylaxis Market Size by Therapy<\/p>\n

14.7.2. Surgical Site Infections – Treatment Market Size by Therapy<\/p>\n

15. Market Drivers<\/p>\n

16. Market Barriers<\/p>\n

17. SWOT Analysis<\/p>\n

18. Unmet Needs<\/p>\n

19. Appendix<\/p>\n

19.1. Bibliography<\/p>\n

19.2. Report Methodology<\/p>\n

20. DelveInsight Capabilities<\/p>\n

21. Disclaimer<\/p>\n

22. About DelveInsight <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Surgical Site Infection Market Insights, Epidemiology, and Market Forecast \u2013 2030\u2019 report deliver an in-depth understanding of the Surgical Site Infection (SSI), historical and forecasted epidemiology as well as the market trends in the United … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-556983","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556983"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556983\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}